Imfinzi is first and only immunotherapy to show survival ... - AstraZeneca
Jun 2, 2024 · Positive results from the ADRIATIC Phase III trial showed AstraZeneca’s Imfinzi (durvalumab) demonstrated statistically significant and clinically meaningful improvements in …
IMFINZI® (durvalumab) | Immunotherapy for Certain Cancers
IMFINZI® (durvalumab) is an immunotherapy approved to treat patients with unresectable hepatocellular carcinoma, bile duct cancer, gallbladder cancer, NSCLC, ES-SCLC, and …
Imfinzi approved in the US as first and only immunotherapy …
Dec 5, 2024 · AstraZeneca’s Imfinzi (durvalumab) has been approved in the US for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not …
IMFINZI® (durvalumab) is the first and only ... - AstraZeneca US
Jun 2, 2024 · Positive results from the ADRIATIC Phase III trial showed AstraZeneca’s IMFINZI ® (durvalumab) demonstrated statistically significant and clinically meaningful improvements in …
Imfinzi approved in the US for the treatment of ... - AstraZeneca
Aug 16, 2024 · Imfinzi is the only approved immunotherapy and the global standard of care in the curative-intent setting of unresectable, Stage III NSCLC in patients whose disease has not …
IMFINZI® (durvalumab) plus chemotherapy approved in ... - AstraZeneca US
Sep 5, 2022 · AstraZeneca’s IMFINZI ® (durvalumab) has been approved in the US for the treatment of adult patients with locally advanced or metastatic biliary tract cancer (BTC) in …
AstraZeneca's Imfinzi recommended for approval in EU
1 day ago · AstraZeneca research and development oncology haematology executive vice-president Susan Galbraith stated: “With 57% of patients still alive at three years in the …
FDA approves AstraZeneca's Imfinzi for LS-SCLC treatment
Dec 5, 2024 · The US Food and Drug Administration (FDA) has approved AstraZeneca‘s human monoclonal antibody, Imfinzi (durvalumab), to treat limited-stage small cell lung cancer (LS …
IMFINZI® (durvalumab) approved in the US as first and only ...
Dec 5, 2024 · AstraZeneca’s IMFINZI ® (durvalumab) has been approved in the US for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease …
AstraZeneca scores FDA nod for Imfinzi as first immunotherapy …
Dec 5, 2024 · AstraZeneca has picked off another label expansion for its cancer blockbuster Imfinzi (durvalumab) as the FDA has blessed the PD-L1 inhibitor for limited-stage small cell …